Search
-
The Minkui Luo Lab
… Job Title Research Fellow Start Year 2019 Email [email protected] Lab Phone 646-888-3281
-
Bone Marrow Transplant SpecialistI am a bone marrow transplant specialist and cellular therapist. I specialize in blood cancers, stem cell transplantation, and chimeric antigen receptor (CAR) T cell therapy for multiple myeloma and lymphomas. My practice is located in New York City.
… Bone Marrow Transplant Specialist & Cellular Therapist Job Title Associate Attending Physician Treatments & Procedures Stem cell transplant Bone marrow transplant CAR T-cell therapy Cellular therapy Education & Honors Education MD, Temple University School of Medicine (2008) Residencies Internal Medicine
-
Bone Marrow Transplant Specialist… Bone Marrow Transplant Specialist & Cellular Therapist Job Title Médica adjunta asistente Treatments & Procedures Trasplante de células madre Trasplante de médula ósea Terapia de células T con CAR Terapia celular Education & Honors Education MD, Temple University School of Medicine (2008) Residencies
-
Patient & Caregiver Education
This checklist will help you get ready for your endoscopic submucosal dissection (ESD) procedure with an upper endoscopy at MSK. It will also help you keep track of what to do the day of your procedure and after your procedure.
-
The Maria Jasin Lab
… Job Title Senior Research Scientist Degree PhD Email [email protected] Lab Phone 212-639-8384 Publications Kass, E.M., Lim, P.X., Helgadottir, H.R., Moynahan, M.E., and Jasin, M. (2016a). Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. Nat Commun
-
Learn the symptoms of Wilms’ tumor and other kidney tumors in children and how these tumors are diagnosed at MSK Kids.
… What are the symptoms of a kidney tumor? Some kidney tumors don’t cause any symptoms. They can be found during a routine exam, when a child’s doctor feels a lump in the belly. When a tumor does cause symptoms, they may include abdominal pain, blood in the urine, and/or high blood pressure. If your child
-
NewsTargeted Drug Shows Promise Against HER2-Positive Breast Cancer That Stops Responding to Other Drugs
MSK medical oncologist Shanu Modi is the lead author of a new paper detailing the results from a phase II trial of a breast cancer drug called trastuzumab deruxtecan or DS-8201a. Results from this study were also presented at the San Antonio Breast Cancer Symposium.
… Wednesday, December 11, 2019 Summary A new study in the New England Journal of Medicine details the results from a phase II trial of a breast cancer drug called trastuzumab deruxtecan or DS-8201a. MSK medical oncologist Shanu Modi is the lead author of the paper, which was also presented at the San Antonio
-
News
Researchers have discovered a simple way to keep stem cells in a more flexible state for research and potential treatments.
… Thursday, June 27, 2019 Summary Stem cells that are pluripotent can develop into any cell type. These stem cells are easier to work with in their earlier naive state of pluripotency. Researchers have discovered that a commonly used fat-free culture medium can shift human stem cells closer to this naive
-
News
Up to 20 percent of people over the age of 70 have clonal hematopoiesis of indeterminate potential (CHIP), a condition that carries twice the risk of coronary heart disease and ischemic stroke, and worse outcomes after heart failure — independent of traditional cardiovascular risk factors.
… Tuesday, October 8, 2019 Up to 20 percent of people over the age of 70 have clonal hematopoiesis of indeterminate potential (CHIP), a condition that carries twice the risk of coronary heart disease and ischemic stroke, and worse outcomes after heart failure — independent of traditional cardiovascular
-
News
在 70 岁以上的人群中,高达 20% 的人有不确定潜能的克隆性造血 (CHIP),这种情况会带来双倍冠心病和缺血性中风风险,并且导致心力衰竭后预后更差 — 无论传统的心血管风险因素如何。
… Tuesday, October 8, 2019 在 70 岁以上的人群中,高达 20% 的人有不确定潜能的克隆性造血 (CHIP),这种情况会带来双倍冠心病和缺血性中风风险,并且导致心力衰竭后预后更差 — 无论传统的心血管风险因素如何。 该状况包括由造血干细胞中的体细胞突变引起的外周血突变白细胞。随着人口老龄化的增长,越来越多 CHIP 患者将前往心血管医生处就诊。 就使用 CHIP 筛查、评估和管理患者的最佳方法,仍存在一些疑问。我们和其他癌症研究中心的同事们一起,最近在 《美国心脏病学会杂志》 上发表了一篇论文。我们在论文中对 CHIP 进行了说明,回顾了一些临床问题,为 CHIP 患者的心血管风险管理提供了一些合理化建议